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87 hours and 32 minutes. The staff spent on average 85 minutes in IV-PCA related 
activities, of which the nurse spent 98%. The average cost, including material and 
staff, for 24-hour usage of IV-PCA was a58.38. The patients thought that their pain 
was under control and they did not think it could be treated better, but they had some 
problem with pain when breathing or expectorating. According to the staff the IV-PCA 
system was easy to use for the patient but hindered their mobilization. CONCLU-
SIONS: IV-PCA involves many different roles and activities and intertwined sub pro-
cesses. Therefore the whole system is complex and resource demanding. Comparisons 
of the results from similar studies at other hospitals will be very useful when optimiz-
ing the process.
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OBJECTIVES: Sickle cell disease (SCD) is an inherited disorder predominantly affect-
ing people of African descent, and is characterized by the production of defective 
hemoglobin. Patients with SCD may experience intermittent and sometimes life-threat-
ening complications often leading to frequent hospitalizations. Hydroxyurea (HU) is 
the only pharmacologic intervention approved (in 1998) for the treatment of adult 
SCD. This study expands upon previous research (Lanzkron et al, 2006) and generates 
national estimates of changes in SCD-related hospitalization rates and associated 
resource use in the United States (US) following approval of HU. METHODS: Dis-
charge data from the 1996–2005 HCUP Nationwide Inpatient Samples for adult (q20 
years) African American (AA) patients with a primary SCD diagnosis (ICD-9-CM 
codes 282.6, 282.6x) were analyzed. Weighted, age-standardized hospitalization rates, 
and estimates of total charges and length of stay (LOS) were calculated for the 2 years 
before (1996–1997) and 8 years (1998–2005) following approval of HU. RESULTS: 
The age-standardized rate of SCD-related hospitalizations (per 10,000 2008 US adult 
AA population) has fallen appreciably from just before HU’s approval in 1997 to 
2005, from 17.3/10,000 to 13.8/10,000, a reduction of ~20%. During this period, the 
mean LOS has remained roughly unchanged (~6 days), though interestingly, mean 
total charges (in 2008 USD) incurred during an SCD-related stay have increased nearly 
65%, from $15,197 in 1997 to $25,005 in 2005. CONCLUSIONS: We examined 
changes in rates of SCD-related hospitalizations and associated outcomes among AA 
patients following approval of HU for treatment of adult SCD. We observed a general 
decrease in the rate of hospitalizations over the ﬁrst 7 years following approval of 
HU. However, little difference in LOS was seen, and total charges for this patient 
group have increased appreciably for unknown reasons. Clinicians and other decision-
makers should be aware of the impact that HU appears to have on SCD-related inpa-
tient outcomes.
SYSTEMIC DISORDERS/CONDITIONS – Patient-Reported Outcomes 
Studies
PSY37
IMPACT OF TOLVAPTAN ON SELF-REPORTED UTILITY SCORES IN 
HYPONATREMIC PATIENTS
Cyr PL1, McInnis M1, Slawsky K1, Krasa H2, Czerwiec F2, Ouyang J2, Goss TF3, Verbalis JG4
1Boston Healthcare Associates, Inc., Boston, MA, USA, 2Otsuka Pharmaceutical Development 
& Commercialization, Inc., Rockville, MD, USA, 3Boston Healthcare Associates, Inc., 
Washington, DC, USA, 4Georgetown Medical Center, Washington, DC, USA
OBJECTIVES: Cognitive and neurologic dysfunction, the most common physiological 
manifestations of hyponatremia, can signiﬁcantly impair individuals’ health-related 
quality of life (HRQOL). Therapeutic correction of hyponatremia should focus not 
only on normalization of serum sodium, but improvement of patients’ functional 
utility as well. We examined the average change in utility scores from initiation of           
either tolvaptan therapy or standard of care (SOC) to day-7 and day-30 post-initiation. 
Standardized utility scores were derived from SF-12 scores from pooled SALT (Study  
of Ascending Levels of Tolvaptan in Hyponatremia) I and II data. METHODS: SF-12 
scores were mapped to the EQ-5D and utility scores were derived using methodology 
developed by Gray, et.al, 2006. Mean change from baseline was assessed for both 
tolvaptan and standard of care (SOC) patient cohorts at day-7 and day-30, quantiﬁed 
as both absolute and percent change. Differences from baseline to day-7 and day-30 
were assessed using a student’s t test. RESULTS: All patients in the SALT trials had 
a baseline serum sodium 135 mEq/L. From baseline to day-7, the mean increase in 
utility score for tolvaptan patients (n  180) was 0.084, compared to an increase of 
0.032 for patients receiving SOC (n  163) (p  0.183). A statistically signiﬁcant mean 
increase in utility was associated with tolvaptan use from baseline to day 30 post-
therapy initiation compared with SOC (p  0.005). The mean increase in utility score 
at day 30 for patients receiving tolvaptan (n  150) was 0.108, whereas utility scores 
for patients receiving SOC (n  164) had returned to baseline values by day-30, with 
a mean change from baseline of 0.001. CONCLUSIONS: Tolvaptan use for hypona-
tremia is associated with an increase in utility compared with SOC, evident at day-7 
and statistically signiﬁcant (p  0.005) at day-30. Utility for tolvaptan patients 
increased from day-7 to day-30 while those for SOC decreased to baseline during this 
period.
PSY38
ELICITING HEALTH STATE UTILITIES FOR IMMUNE (IDIOPATHIC) 
THROMBOCYTOPENIC PURPURA: RESULTS OF A GENERAL PUBLIC 
BASED TIME TRADE-OFF SURVEY
Arnold DM1, Tinmouth A2, Iskedjian M3, Gafni A1, Deuson R4, Isitt J5, Mikhael J6
1McMaster University, Hamilton, ON, Canada, 2Department of Medicine, University of 
Ottawa, Ottawa, ON, Canada, 3PharmIdeas Research and Consulting Inc, Oakville, ON, 
Canada, 4Amgen, Thousand Oaks, CA, USA, 5Amgen Inc, Thousand Oaks, CA, USA, 6Mayo 
Clinic Arizona, Scottsdale, AZ, USA
OBJECTIVES: The objective of this study was to measure health state utilities associ-
ated with Immune Thrombocytopenic Purpura (ITP), as perceived by members of the 
Canadian general public. METHODS: An electronic version of the Time Trade-off 
(TTO) method was developed and administered to a sample of the general public in 
Canada. Twelve distinct health states were deﬁned based on severity of bleeding, 
presence of other adverse events, and whether treatment was with romiplostim (a new 
thrombopoietin mimetic agent) or standard of care. Results from two 24-week ran-
domized controlled phase 3 trials were used in developing health state descriptions. 
Pilot surveys were developed to ensure ease of use and to improve measurement 
characteristics of the ﬁnal survey. A sample of 813 subjects was needed for power 
0.90 and an alpha error of 0.05. Utility scores were reported as mean, median and 
range for each health state and compared using Dunn’s post-hoc test. RESULTS: After 
two pilot tests on 126 participants, 821 adults [mean age 36.4 (range 22–80) years, 
63% female] from Ontario, Canada, completed the TTO valuation survey. Mean (SD) 
utility scores ranged from 0.476 (0.271) for the most severe health state describing 
signiﬁcant bleeding to 0.633 (0.282) for the health state depicting successful treatment 
with romiplostim without bleeding. Mean differences between the most severe bleed-
ing health state and 5 other health states were statistically signiﬁcant (p  0.05 for 
each). CONCLUSIONS: The Canadian general public had decreased preference for 
the most severe ITP health states with signiﬁcant bleeding. Respondents most preferred 
ITP health states with no bleeding combined with successful treatment with romip-
lostim. The utility scores derived from these 12 health states can be used as to inform 
cost-effectiveness models of romiplostim as a treatment for ITP in Canada.
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OBJECTIVES: Phenylketonuria (PKU) and its dietary management have a substantial 
effect on quality of life (QOL) of patients and their families. There is little published 
research that quantiﬁes these effects in this orphan disease. The study explores the 
impact of PKU and its severity on QOL by eliciting utilities from a sample of general 
population. METHODS: Health state descriptions were developed for children and 
adults from the literature and expert interviews (n  3) and validated by different clini-
cians (n  3). Health states for children were: controlled (designated by target phenyl-
alanine levels) by diet or medication for severe or mild/moderate disease; uncontrolled 
irrespective of severity. Adults’ states were: controlled by diet or medication; uncon-
trolled. 100 participants across four UK centres were presented randomly with health 
state descriptions which were valued using the EQ-5D questionnaire and TTO (Time-
trade-off) exercise to produce utility values. RESULTS: For both children and adults 
health states, the highest utility was attributed to health states controlled by medicine 
for both the EQ-5D and TTO (Children: severe 0.71–0.91, mild/moderate 0.76–0.94. 
Adults: 0.79–0.83). The uncontrolled state is associated with a lower utility score 
across groups and instruments. The EQ-5D scores were lower compared to TTO 
(particularly for children where parents found difﬁculty in trading off length of life). 
The addition of a drug, adjunct to diet, had larger effect on the EQ-5D score. Utilities 
for children were higher than adults across methods CONCLUSIONS: This small 
study provides evidence of a QoL impact of phenylketonuria. In both TTO and EQ-5D 
valuations, utilities were higher in controlled compared to uncontrolled state in chil-
dren and adults. The addition of an effective drug, adjunct to diet, to control PKU 
improved utility further. This research also provides insight into the difﬁculties mea-
suring utility in orphan diseases where natural history is hard to deﬁne.
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OBJECTIVES: Hemophilia is a rare and intractable disease. Although it is a rare, the 
per-capita cost of the disease covered by health insurance budget is high. The genera-
tion of patients with inhibitors incurs higher expenses and is prone to complications. 
This study compares treatment and medication pattern by the presence of inhibitors. 
METHODS: A survey was conducted for 99 patients without inhibitors and 32 
patients with inhibitors. Age distribution of patients was similar to the actual distribu-
tion of patients. The rate and frequency of hospitalization, treatment-related tests, 
adjuvant treatment and the rate of complications were examined. In addition, patients’ 
age, drugs in use, the number of hospital visits, and the number of drug administration 
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were surveyed. SAS Version 9.1 (SAS Institute Inc. Cary, NC, USA) was used for data 
analysis. RESULTS: Patients with inhibitors showed higher rate (78%) and frequency 
(2.33 times per year) of hospitalization than those without inhibitors (42%, 1.13 times 
respectively). Also the rate of complications was higher (81%) compared with 59% 
for those without inhibitors. However, patients without inhibitors and those with 
inhibitors did not show statistically signiﬁcant results in hospital visits, drug adminis-
tration status, treatment-related tests (excluding blood tests), and adjuvant treatment. 
CONCLUSIONS: Patients with inhibitors are exposed to higher risk of bleeding and 
complications, which results in a more expensive medical utilization. In this regard, 
more active public subsidy program needs to be developed to prevent the generation 
of inhibitors.
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OBJECTIVES: The objective was to measure health states (HS) associated with 
Immune (Idiopathic) Thrombocytopenic Purpura (ITP), as perceived by members of 
the UK general public. METHODS: Six distinct ITP HS were deﬁned based on platelet 
levels, risk of bleeding, and key adverse events/disease complications. Clinical trial 
data on bleeding and ITP-speciﬁc quality of life data were key sources for developing 
HS descriptions. After a pilot survey, sample size calculation was based on combina-
tions of detectable differences in utility scores between HS, power, and standard 
deviation (SD). A total of 359 respondents, who were randomly selected from a        
managed panel that includes 300,000 individuals in the UK, completed the web-based 
Time Trade-Off survey Sampling and tracking quotas on respondent demographic       
characteristics were performed to ensure representativeness. The Wilcoxon signed 
rank test was used to compare each pair of HS. RESULTS: Sample characteristics 
(mean age: 47.9 years, SD: 16.9; 54% female) were comparable to the UK general 
population. ITP HS were valued as signiﬁcantly worse than perfect health. Experienc-
ing episodes of bleeding was a more important driver than low platelet levels in valuing 
a HS to be worse. Substantial disutilities were associated with surviving an intracranial        
haemorrhage. Mean utility scores for the ITP HSs: HS1: Platelets          q50x109/L, no out-
patient bleed: 0.863 (SD:0.15) HS2: Platelets q50x109/L, outpatient bleed: 0.734 
(SD:0.19) HS3: Platelets 50x109/L, no outpatient bleed: 0.841 (SD:0.19) HS4: Plate-
lets 50x109/L, outpatient bleed: 0.732 (SD:0.19) HS5: Intracranial haemorrhage (2–6 
months): 0.038 (SD:0.46) HS6: Steroid treatment adverse events: 0.758 (SD:0.20) 
CONCLUSIONS: This survey provided evidence that members of the UK general 
population associate a substantial loss of value living in ITP HS. These ﬁndings suggest 
an important role for new ITP treatments and utility scores gained from this survey 
can be used in future cost-effectiveness studies.
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OBJECTIVES: Von Willebrand disease (VWD) is a bleeding disorder affecting about 
1% of the general population. This study explored relationships between bleeding 
disorders, menorrhagia, iron deﬁciency and HRQL. It was hypothesized that females 
with bleeding disorders would have low HRQL associated with menorrhagia and iron 
deﬁciency. METHODS: All males and females with VWD, and females with other 
bleeding disorders, in the Canadian national registry, who were older than 12 years 
of age and literate in English or French, were eligible for survey in this cross-sectional 
population-based study. Measures included the Health Utilities Index Mark 3 utility 
scores of HRQL; abridged Clinical History Assessment Tool for menorrhagia; socio-
demographic questions; and blood for serum ferritin. Iron deﬁciency was deﬁned as 
serum ferritin a20 mcg/L. Statistical analyses included testing differences among 
groups of means using analysis of variance, and of proportions using chi-square. Sta-
tistical signiﬁcance was set at the 5% level. RESULTS: 413 subjects participated. There 
was a signiﬁcant difference (p  0.026) among mean HRQL scores for females with 
VWD (0.701), females with other bleeding disorders (0.783) and males with VWD 
(0.767). Among menstruating females (n  185), there was: no signiﬁcant difference 
(p  0.108) in mean HRQL scores between females with VWD and females with other 
bleeding disorders; a high (p  0.001) prevalence of menorrhagia (44%) compared to 
controls (11%); a signiﬁcant difference (p  0.001) in mean HRQL scores for those 
with / without (0.643 / 0.816) menorrhagia; and no association (p  0.740) between 
menorrhagia and iron deﬁciency. CONCLUSIONS: Females with VWD have lower 
HRQL than females with other bleeding disorders and males with VWD. Menorrhagia 
is prevalent and associated with lower HRQL, but not iron deﬁciency, among men-
struating females with bleeding disorders. Future research should investigate better 
management of menorrhagia for improving HRQL.
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OBJECTIVES: To develop the functions of mapping the 24-item Roland Morris Dis-
ability Questionnaire (RMDQ) for back pain into the EQ-5D and SF-6D utility index. 
METHODS: Data were obtained from the UK BEAM trial, a multi-centre randomised 
trial of physical treatments for back pain in primary care. A total of 1334 patients 
were recruited and completed a battery of questionnaires, including RMDQ, EQ-5D 
and SF-36v2 at the baseline, 1, 3 and 12-month follow-ups. The responses of SF-36v2 
were converted into SF-6D using the published algorithm. Data were divided into two 
groups: one to estimate the mapping functions through regression methods and the 
other to validate the mapping functions. Both overall dataset and sub-datasets of each 
follow-up were examined separately RESULTS: Ordinary least square (OLS) regres-
sion with summary score of RMDQ as independent variable explained 27, 39, 46 and 
53% of variance of observed EQ-5D scores for each follow-up, respectively. Based on 
the overall dataset, OLS regression explained 40 and 44 % of variance with the 
summary score and 18 items of RMDQ as independent variables, respectively. 
However, the mean absolute difference (MAD) of all above models was greater than 
0.13. Meanwhile, models for mapping RMDQ into SF-6D explained only 1 to 4% of 
variance amongst all examined models and datasets. CONCLUSIONS: Based on the 
current ﬁndings, the score of RMDQ for back pain cannot be mapped into the SF-6D 
utility score. The possible cause could be the lack of over-lapping domains between 
two measures. The mapping of RMDQ into EQ-5D could be feasible but applied at 
the group level only. The correlation between RMDQ and EQ-5D increased when 
patients’ pain condition improved. Consequently, the choice of input dataset, overall 
or subset, has a great impact on estimating functions. The ﬁnial selected dataset for 
mapping needs to be justiﬁed.
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Haemophilia is a congenital bleeding disorder with a prevalence of 1:10,000 inhabit-
ants. Treatment of patients with haemophilia requires a substantial amount of eco-
nomical and human resources, why patient-rated outcomes (PROs) such as Quality 
of Life (QoL) and treatment satisfaction (TS) are considered increasingly more impor-
tant in this ﬁeld. For the adequate assessment of PROs cross-culturally validated 
disease-speciﬁc instruments are necessary. OBJECTIVES: Linguistic validation of 3 
haemophilia-speciﬁc PROs for the assessment of TS (Hemo-Sat) and QoL, both in 
children (Haemo-QoL: 3 age group versions for children 4–7, 8–12, 13–16 years and 
their parents) and in adults (Haem-A-QoL) in up to 32 languages. METHODS: For 
languages where no translation existed, the process was conducted by a specialist in 
each target country using the following standardized methodology: (1) two forward 
translations by professional translators, native speakers of the target language and 
ﬂuent in English; (2) comparison and reconciliation of the translations by the specialist 
in the target country; (3) backward translation by a native English speaker; (4) com-
parison of source and backward version; (5) review by the developer for a selection 
of languages; creation of the different forms of the instrument; (6) review by a clini-
cian. RESULTS: The Haemo-QoL was linguistically validated into 32 languages, 
Haem-A-QoL (n  29) and Hemo-Sat (n  19). Besides the challenge of ensuring con-
ceptual equivalence with the original and cultural appropriateness, the translation 
process revealed 2 additional difﬁculties. When translating an expression, appropriate 
terms had to be found for each age group whilst maintaining consistency across all 
versions of the same language. CONCLUSIONS: The language versions of Haemo-
QoL, Haem-A-QoL and Hemo-Sat were established according to a rigorous transla-
tion methodology aiming to ensure conceptual equivalence across different language 
versions facilitating international comparison and pooling of data. The linguistic vali-
dation process is necessary before using PROs in international trials.
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OBJECTIVES: Severe Crohn’s disease management includes anti-Tumour Necrosis 
Factor (anti-TNF) drugs. These drugs differ from the treatments used in early stages 
of the disease in terms of efﬁcacy, safety and convenience. This can modify the impact 
of the disease and its treatment on patients’ lives. The objective of the study was 
to develop a questionnaire assessing patients’ satisfaction with anti-TNF treatments 
in Crohn’s disease. METHODS: A literature review, 3 clinician interviews and 3 
interviews with nurses were carried out as a preparation step. Semi-directive patient 
